INCYTE CORP. news, videos and press releases - Page 3
For more news please use our advanced search feature.
INCYTE CORP. - More news...
INCYTE CORP. - More news...
- Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
- More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
- Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
- Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
- Incyte to Report Third Quarter Financial Results
- Incyte Names New Member to Its Board of Directors
- Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
- Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
- Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
- Incyte to Present at Upcoming Investor Conference
- Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
- Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
- Incyte to Report Second Quarter Financial Results
- Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
- Incyte to Present at Upcoming Investor Conference
- Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
- Incyte to Present at Upcoming Investor Conference
- Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
- Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
- Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
- Incyte to Report First Quarter Financial Results
- Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
- Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
- Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
- Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
- Incyte to Present at Upcoming Investor Conference
- Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
- Incyte to Present at Upcoming Investor Conference
- Incyte Provides Update on Parsaclisib and MCLA-145
- Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
